$170,000 Colorado Grant will advance Cetya’s novel targeted HDAC inhibitor program.
Recent Posts
- Cetya Therapeutics Announces Issuance of Process Patent Covering Novel Synthesis of its HDAC Inhibitors
- Cetya Therapeutics welcomes Dr. Anthony Wutoh to its Board of Directors
- Cetya Therapeutics Appoints Ron Lowy to Board of Directors
- Cetya Therapeutics Announces Issuance of New Patents Covering its HDAC Inhibitor CT-102
- Cetya Therapeutics Announces Issuance of New Patent Covering Its Unique Targeted HDAC Inhibitors